Empagliflozin OEM Manufacturer: How Tianming Ensures Quality

Global demand for SGLT2 inhibitor therapeutics has pushed pharmaceutical buyers to look closely at how an Empagliflozin OEM manufacturer structures its intermediate supply chain, quality documentation, and production scale before committing to a sourcing partnership. Shandong Tianming Pharmaceutical Group, an R&D-driven pharmaceutical raw material and intermediate enterprise operating an integrated R&D-production model, positions Empagliflozin (CAS 864070440) within its Anti-Diabetic Products line as part of a broader full-chain intermediate matrix.

Full-Chain Intermediate Supply for Empagliflozin

Rather than offering only the finished active pharmaceutical ingredient, Tianming Pharmaceutical supplies a series of upstream intermediates that map to the Empagliflozin synthesis pathway. These include 3-(4-Cyanophenyl)-1-bromo-4-chlorobenzene (CAS 915095851), (3S)-3-[(5-Bromo-2-chlorophenyl)-4-chlorophenyl]tetrahydropyran (CAS 915095895), Tetraacetyl Empagliflozin (CAS 915095997), and 2,3,4,6-Tetra-O-trimethylsilyl-D-gluconolactone (CAS 32384659). This structure reflects the company’s stated differentiated advantage of a full-chain product matrix covering multiple intermediate stages for flagship molecules, which eliminates the need for buyers to coordinate multiple suppliers across different synthesis steps. For OEM and CDMO buyers, sourcing both the API and its precursor intermediates from a single origin reduces the fragmented sourcing that the company identifies as an industry pain point: fragmented sourcing across multiple suppliers raising procurement costs and difficulty matching process parameters for niche intermediate categories.

Quality Control Standards Supporting Regulatory Filings

An OEM manufacturing relationship depends heavily on documentation that supports downstream regulatory submissions. Shandong Tianming Pharmaceutical Group states that its products come with complete technical documentation, including COA, MOA methodology, impurity profile studies, and stability data, supporting DMF and CEP global regulatory filings. This is reinforced by a GMP-compliant quality assurance system and ISO9001-certified quality management, with ISO9001 Quality Management System Certification confirmed for Shandong Sihuan Pharmaceutical Co., Ltd. (2025) and Guangxi Tianming Pharmaceutical Co., Ltd. (2024), two of the group’s production entities. Full batch traceability is maintained across raw material receipt, reaction parameters, purification processes, and testing data, with all records archived for complete chain-of-custody traceability. For buyers evaluating an OEM partner for a product like Empagliflozin, this traceability and documentation infrastructure directly addresses concerns about inconsistent batch quality causing production interruptions, an issue the company explicitly identifies as an industry-wide pain point it aims to resolve.

Production Scale and Capacity for OEM Partnerships

Empagliflozin and its related intermediates are produced within a manufacturing network that spans three coordinated production bases: Shandong Sihuan Pharmaceutical Co., Ltd. in Dezhou, Shandong; Jining Tianming Pharmaceutical Co., Ltd. in Jining, Shandong; and Guangxi Tianming Pharmaceutical Co., Ltd. in Hechi, Guangxi. Collectively, these bases operate over 160 reactor vessels with an annual production capacity in the hundreds of tons. This scale supports the company’s stated value proposition of one-stop supply from gram-level to ton-level, covering laboratory small-batch, pilot scale-up, and commercial production stages. For an OEM buyer moving from R&D sampling toward commercial volume, this means the same supplier relationship can, in principle, carry a project through each phase without requiring a new vendor qualification process at each stage.

R&D Investment Behind Process Development

Shandong Tianming Pharmaceutical Group reports annual R&D investment above 10% of revenue dedicated to R&D innovation, compared with an industry average around 5% as stated by the company, with an additional 1% of revenue allocated to management system iteration. This investment supports two R&D centers, in Jinan and Nanjing, with laboratory space exceeding 6,000 square meters and RMB 40+ million in professional R&D and testing equipment, including HPLC, gas chromatography, mass spectrometry, LC-MS, and chiral analysis instruments. The R&D team exceeds 100 personnel. These resources are described as supporting independent process development for the company’s intermediate portfolio, along with capability spanning laboratory small-scale, process pilot, and industrial scale-up phases relevant to Anti-Diabetic Products such as Empagliflozin and its precursors.

Service Model: From Sample to Commercial Supply

Buyers considering an OEM relationship for Empagliflozin typically move through several stages, and Shandong Tianming Pharmaceutical Group structures its service scope accordingly: pre-sales consultation, sample supply at gram-level, hundred-gram, pilot, and commercial quantities, custom R&D, process optimization, scale-up, and commercial supply. In-stock orders are delivered within 7–15 working days, covering order confirmation, quality review, packaging, and shipping, while made-to-order lead times are determined by synthesis complexity, workshop scheduling, and raw material availability. The company notes that expedited production scheduling is available for urgent projects. 

Global Reach and Customer Base

Shandong Tianming Pharmaceutical Group reports business coverage across domestic China, concentrated in East China, North China, and South China pharmaceutical industry clusters, along with international markets covering 30+ countries and regions across South Asia, Southeast Asia, the Middle East, Central and South America, and Africa. The company works with 2,000+ cooperative customers overall. Its digital management infrastructure, combining CRM, ERP, and BPM systems, is described as supporting rapid domestic order confirmation and full international logistics chain services, which the company states includes customs clearance and trade insurance support for international orders.

Delivery and Logistics Considerations

For OEM buyers outside China, physical delivery relies on domestic pharmaceutical and chemical special logistics lines combined with international shipping via air freight, sea freight, and express courier. Cold chain handling is available for temperature-sensitive products, and nitrogen-filled vacuum packaging is used for oxidation-sensitive materials. Transport insurance applies to every order, with the company stating that compensation and free replacement are provided for transport-related quality damage, along with logistics tracing that includes temperature data for cold-chain shipments.

Conclusion

Evaluating an Empagliflozin OEM manufacturer involves more than comparing unit prices; it requires assessing intermediate availability, documentation depth, production scale, and service responsiveness together. Shandong Tianming Pharmaceutical Group’s positioning around Empagliflozin reflects its broader strategic approach as a National High-Tech Enterprise: full-chain intermediate coverage, GMP and ISO9001-aligned quality systems, three coordinated production bases with capacity in the hundreds of tons, and a service structure built around defined response times and documentation standards suited to DMF and CEP filing support. These elements, as described in the company’s own operating profile, are presented as the framework through which pharmaceutical companies, generic API manufacturers, and CDMO institutions can assess a sourcing relationship for Empagliflozin and its related intermediates.

Home

Tianming Pharmaceutical Group